A pharmaceutical composition of the present invention, comprising a compound represented by chemical formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof in an amount of 7-90 mg with respect to the weight of a free base, can be effectively used for preventing or treating diabetes via daily administration.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61K 9/00 - Medicinal preparations characterised by special physical form
A compound represented by chemical formula 1 or 2, according to the present invention, as a ubiquitin-specific-processing protease 1 (USP1) inhibitor, can be useful for the prevention or treatment of cancer.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Cosmetics; Cosmetic preparations for skin care; Cosmetic preparations for the hair and scalp; Cosmetic preparations for hair care; Cosmetic preparations for body care; Make-up for the face and body; Anti-wrinkle creams; Wrinkle removing skin care preparations; Wrinkle-minimizing cosmetic preparations for topical facial use; Facial moisturizers; Impregnated cleaning pads impregnated with cosmetics; Skin cleansers; Cosmetic soaps; Shampoos; Solid shampoo bars; Dry shampoos; Hair conditioners; Hair rinses; Essential oils for personal use; Toothpaste
4.
NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME
The compound represented by chemical formula 1 of the present specification can be usefully employed as a ubiquitin-specific-processing protease 1 (USP1) inhibitor for prevention or treatment of cancer.
The present invention relates to a pharmaceutical composition comprising, as active ingredients. ezetimibe or a pharmaceutically acceptable salt thereof and fenofibrate or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition and a preparation method therefor, the pharmaceutical composition comprising a certain antioxidant so as to reduce the degradation of ezetimibe and the generation of related substances, and improve the stability of the pharmaceutical composition, thereby maintaining excellent efficacy.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Cosmetics; Anti-wrinkle creams; Cosmetic preparations for body care; Cosmetic preparations for hair care; Cosmetic preparations for skin care; Cosmetic preparations for the hair and scalp; Cosmetic soaps; Dry shampoos; Essential oils for personal use; Facial moisturizers; Hair conditioners; Hair rinses; Impregnated cleaning pads impregnated with cosmetics; Make-up for the face and body; Shampoos; Skin cleansers; Solid shampoo bars; Wrinkle-minimizing cosmetic preparations for topical facial use; Wrinkle removing skin care preparations
7.
NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
The present invention provides a compound represented by chemical formula 1 in the specification or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising the compound as an active ingredient can be advantageously used for the prevention or treatment of BAF complex-related diseases.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention promotes the expression of the myogenic factors MyoG and MyHC while inhibiting the expression of the muscle atrophy factor atrogin-1, promotes the formation of myotubes, and inhibits myocyte apoptosis, and thus can promote myogenesis and inhibit muscle atrophy.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
9.
METHOD FOR EVALUATING QUALITY OF (3S)-3-(4-(3-(1,4-DIOXASPIRO[4,5]DEC-7-EN-8-YL)BENZYLOXY)PHENYL)HEX-4-INOIC ACID
The present invention provides a related substance of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-inoic acid, and a method for evaluating the quality of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en yl)benzyloxy)phenyl)hex-4-inoic acid using the same. According to the present invention, it is possible to evaluate the quality, stability and the like of a pharmaceutical composition comprising (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-inoic acid using a compound of Chemical Formula 2 or a salt thereof as a reference standard.
6 are as described herein, or a pharmaceutically acceptable salt thereof, which serves as a GLP-1 receptor agonist and may be useful in the prevention or treatment of a disease associated with GLP-1 activity.
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 235/12 - Radicals substituted by oxygen atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Functional cosmetics being skin care preparations; facial moisturisers; non-medicated facial treatment cream for the treatment of wrinkle or pigmentation; cosmetic moisturizing preparations; serums for cosmetic purposes; cosmetic skin care lotions; cream for whitening the skin; skin whitening preparations, namely, whitening essences in the nature of serums for skincare; anti-wrinkle creams; wrinkle removing skin care preparations; beauty creams for body care; body lotions; moisturizing cream; skin creams in liquid and solid form; cosmetic preparations for the scalp; cosmetics; cosmetic soaps; shampoos; dentifrices; lavender oil
Wholesale store services featuring functional cosmetics being skin care preparations; wholesale store services featuring antiaging cosmetic preparations; wholesale store services featuring body and beauty care cosmetics; wholesale store services featuring cosmetic preparations for the hair and scalp; retail store services featuring body and beauty care cosmetics; retail store services featuring cosmetic preparations for the hair and scalp; wholesale store services featuring cosmetics; retail store services featuring cosmetics; sales agency services for cosmetics in the nature of sales promotion; sales arranging of cosmetics in the nature of arranging of auction sales; business intermediary services relating to the purchase and sale of cosmetics, namely, providing a website for connecting buyer with sellers; online wholesale store services featuring cosmetics via the internet; online retail store services featuring cosmetics via the internet; sales agency services for cosmetics in the nature of sales promotion via the internet; sales arranging of cosmetics in the nature of arranging of auction sales via the internet; business intermediary services relating to the purchase and sale of cosmetics, namely, providing a website for connecting buyer with sellers via the internet; wholesale store services featuring cosmetic soaps; wholesale store services featuring shampoos; wholesale store services featuring dentifrices; wholesale store services featuring lavender oil
Wholesale store services featuring functional cosmetics being skin care preparations; wholesale store services featuring antiaging cosmetic preparations; wholesale store services featuring body and beauty care cosmetics; wholesale store services featuring cosmetic preparations for the hair and scalp; retail store services featuring body and beauty care cosmetics; retail store services featuring cosmetic preparations for the hair and scalp; wholesale store services featuring cosmetics; retail store services featuring cosmetics; sales agency services for cosmetics in the nature of sales promotion; sales arranging of cosmetics in the nature of arranging of auction sales; business intermediary services relating to the purchase and sale of cosmetics, namely, providing a website for connecting buyer with sellers; online wholesale store services featuring cosmetics via the internet; online retail store services featuring cosmetics via the internet; sales agency services for cosmetics in the nature of sales promotion via the internet; sales arranging of cosmetics in the nature of arranging of auction sales via the internet; business intermediary services relating to the purchase and sale of cosmetics, namely, providing a website for connecting buyer with sellers via the internet; wholesale store services featuring cosmetic soaps; wholesale store services featuring shampoos; wholesale store services featuring dentifrices; wholesale store services featuring lavender oil
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Functional cosmetics being skin care preparations; facial moisturisers; non-medicated facial treatment cream for the treatment of wrinkle or pigmentation; cosmetic moisturizing preparations; serums for cosmetic purposes; cosmetic skin care lotions; cream for whitening the skin; skin whitening preparations, namely, whitening essences in the nature of serums for skincare; anti-wrinkle creams; wrinkle removing skin care preparations; beauty creams for body care; body lotions; moisturizing cream; skin creams in liquid and solid form; cosmetic preparations for the scalp; cosmetics; cosmetic soaps; shampoos; dentifrices; lavender oil
16.
ORAL RINSE WITH IMPROVED STABILITY, COMPRISING BENZYDAMINE HYDROCHLORIDE
The present invention relates to an oral rinse, which comprises benzydamine hydrochloride and has stability that is maintained for a long time in a packing material made of polyethylene, and the oral rinse has a slightly acidic pH, and thus has a stability that is maintained for a long time even if packaged in a pouch of a packing material made of polyethylene.
A 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention promotes the expression of the myogenic factors MyoG and MyHC while inhibiting the expression of the muscle atrophy factor atrogin-1, promotes the formation of myotubes, and inhibits myocyte apoptosis, and thus can promote myogenesis and inhibit muscle atrophy.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
C07D 317/72 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
18.
NOVEL CRYSTAL FORM OF 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE
The present invention relates to a novel crystal form of a 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method therefore and a pharmaceutical composition comprising same. A crystal form I of a compound of chemical formula 1, according to the present invention, exhibits more excellent physicochemical properties such as thermal stability, static electricity-inducing capability, compressibility, etc. compared to an amorphous form or a crystal form II, and thus is especially useful for preparation and long-term storage.
C07D 317/72 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Cosmetic preparations for hair care; Hair care creams; Hair care preparations; Hair cleaning preparations; Non-medicated serums for use on hair as essence mists; Non-medicated shampoos for the care of scalp; Non-medicated hair care preparations; Shampoos
20.
METHOD FOR EVALUATING QUALITY OF (3S)-3-(4-(3-(1,4-DIOXASPIRO[4,5]DEC-7-EN-8-YL)BENZYLOXY)PHENYL)HEX-4-INOIC ACID
The present invention provides a related substance of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-inoic acid, and a method for evaluating the quality of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-inoic acid by using same. According to the present invention, It is possible to evaluate the quality and the stability of a pharmaceutical composition comprising (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-inoic acid by using a compound of formula 2 or a salt thereof as a reference standard.
166 are as described herein, or a pharmaceutically acceptable salt thereof, which serves as a GLP-1 receptor agonist and may be useful in the prevention or treatment of a disease associated with GLP-1 activity.
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
C07D 235/24 - BenzimidazolesHydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
On-line retail store services featuring cosmetics, namely, body and beauty care cosmetics, cosmetic preparation for the hair and scalp; Retail store services featuring cosmetics, namely, body and beauty care cosmetics, cosmetic preparation for the hair and scalp; Wholesale store services featuring cosmetics, namely, cosmetic preparations for skin care, anti-aging cosmetic skin care preparations, body and beauty care cosmetics, cosmetic preparations for the hair and scalp, cosmetic soaps, shampoos, dentifrices, lavender oil; On-line wholesale store services featuring cosmetics, namely, cosmetic preparations for skin care, anti-aging cosmetic skin care preparations, body and beauty care cosmetics, cosmetic preparations for the hair and scalp, cosmetic soaps, shampoos, dentifrices, lavender oil
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
dentifrices; shampoos; anti-wrinkle creams; beauty creams for body care; beauty serums; body lotions; cosmetic preparations for skin care; cosmetic preparations for the hair and scalp; cosmetic soaps; cosmetics; cream for whitening the skin; facial cream; facial moisturizers; lavender oil; moisturizing creams; moisturizing preparations for the skin; non-medicated skin care preparations, namely, lotions, creams, ethereal essence, mint essence being essential oil, flower essence for cosmetic purposes, serum, toner; skin care products, namely, non-medicated skin serum; skin creams in liquid and in solid form; skin whitening preparations; wrinkle removing skin care preparations
On-line retail store services featuring cosmetics, namely, body and beauty care cosmetics, cosmetic preparation for the hair and scalp; Retail store services featuring cosmetics, namely, body and beauty care cosmetics, cosmetic preparation for the hair and scalp; Wholesale store services featuring featuring cosmetics, namely, cosmetic preparations for skin care, anti-aging cosmetic skin care preparations, body and beauty care cosmetics, cosmetic preparations for the hair and scalp, cosmetic soaps, shampoos, dentifrices, lavender oil; On-line wholesale store services featuring cosmetics, namely, cosmetic preparations for skin care, anti-aging cosmetic skin care preparations, body and beauty care cosmetics, cosmetic preparations for the hair and scalp, cosmetic soaps, shampoos, dentifrices, lavender oil
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Dentifrices; Shampoos; Anti-wrinkle creams; Beauty creams for body care; Beauty serums; Body lotions; Cosmetic preparations for skin care; Cosmetic preparations for the hair and scalp; Cosmetic soaps; Cosmetics; Cream for whitening the skin; Facial cream; Facial moisturizers; Lavender oil; Moisturizing creams; Moisturizing preparations for the skin; Non-medicated skin care preparations, namely, lotions, creams, ethereal essence, mint essence being essential oil, flower essence for cosmetic purposes, serum, toner; Skin care products, namely, non-medicated skin serum; Skin creams in liquid and in solid form; Skin whitening preparations; Wrinkle removing skin care preparations
26.
NOVEL CRYSTAL FORM OF 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE
The present invention relates to a novel crystal form of a 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a production method therefor and a pharmaceutical composition comprising same. A crystal form I of a compound of chemical formula 1, according to the present invention, exhibits more excellent physicochemical properties such as thermal stability, static electricity-inducing capability, compressibility, etc. compared to an amorphous form or a crystal form II, and thus is especially useful for preparation and long-term storage.
C07D 317/72 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
The present invention provides a use of a 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative for protecting pancreatic beta cells. A 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention resolves a side effect in which conventionally developed agents for treating diabetes induce apoptosis of pancreatic beta cells through excitotoxic reactions, thereby causing a secondary failure in which an insulin secretory function is not controlled. A 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention promotes insulin secretion only when glucose concentration is increased, thereby protecting the pancreatic beta cells from apoptosis and restoring the insulin secretory function of the pancreatic beta cells. Therefore, according to the present invention, the 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative: exhibits an excellent pancreatic beta cell protection effect, when administered as a primary selective agent for diabetes and also when administered to a patient having pancreatic beta cells damaged by the use of other drugs, which are primary selection agents for diabetes and cause a secondary failure; and restores the insulin secretory function of pancreatic beta cells, thereby being useful for treating type II diabetes in a patient of which the blood glucose is not regulated in a normal manner by using an agent for promoting insulin secretion.
C07D 317/06 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
28.
Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
The present invention relates to a cyclohexene derivative, a preparation method thereof, and a pharmaceutical composition for preventing or treating metabolic disease containing the cyclohexene derivative as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.
C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 491/113 - Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to a novel compound inhibiting CDK5-mediated PPARγ phosphorylation, a preparation method therefor, and a pharmaceutical composition containing the same. The novel compound of the present invention binds to PPARγ with high affinity but does not induce transcriptional activity so as not to act as an agonist, does not cause side effects of a conventional anti-diabetic by blocking the phosphorylation activity of CDK5, and has improved pharmacological properties. Therefore, a pharmaceutical composition containing the compound of the present invention as an active ingredient can be usable in the treatment of metabolic diseases associated with PPARγ.
C07D 209/22 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (DPPIV) inhibitor-based, sulfonylurea-based, thiazolidinedione (TZD)-based, biguanide-based, and sodium/glucose cotransporter 2 (SGLT2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type I, diabetes type II, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07C 59/72 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 211/70 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 317/72 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
31.
CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT
The present invention relates to: a cyclohexene derivative; a preparation method thereof; and a pharmaceutical composition for preventing or treating metabolic disease comprising the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.
The present invention relates to a pharmaceutical composition for a hair health or hair growth promotion, containing melatonin, dexpanthenol, biotin and nicotinamide as active ingredients. The composition of the present invention maximizes hair growth or hair health effects by stabilizing a preparation while improving the light stability of melatonin, which is a pharmacologically active ingredient, and significantly inhibiting scalp inflammation. Therefore, the composition of the present invention can be useful as an effective hair growth or hair health promoter or as an agent for preventing or treating hair loss, the composition simultaneously increasing light stability, preservability, convenience of administration and therapeutic effects.
COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES
The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (DPPIV) inhibitor-based, sulfonylurea-based, thiazolidinedione (TZD)-based, biguanide-based, and sodium/glucose cotransporter 2 (SGLT2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type I, diabetes type II, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
34.
3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient
The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc.
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
C07D 217/04 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 317/72 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
C07D 271/07 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 295/073 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07C 51/367 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
C07C 51/373 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in doubly bound form
C07C 59/72 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
C07C 59/90 - Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
C07D 211/70 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 215/04 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
35.
CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT
The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.
C07D 211/06 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
C07D 211/02 - Preparation by ring-closure or hydrogenation
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
36.
COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT
The present invention relates to a compound inhibiting CDK5-mediated PPARG phosphorylation and a pharmaceutical composition for treating PPARG-related diseases containing the same as an active ingredient. A compound represented by chemical formula 1 or an optical isomer thereof according to the present invention binds to PPARG at a high affinity, but does not act as an agonist, thereby inducing no gene transcription; blocks CDK5, which is a cause of PPARG phosphorylation, thereby causing no side effects of existing anti-diabetics; can be formulated into drugs due to improved pharmacological properties thereof; and can be favorably used as a pharmaceutical composition for treating PPARG-related diseases due to an excellent treatment effect on PPARG-related diseases.
C07D 265/36 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
C07D 215/04 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
37.
SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING ACEBROPHYLLINE AND HYDROPHOBIC SUSTAINED-RELEASE AGENT
The present invention relates to a pharmaceutical composition containing acebrophylline thereby having both immediate and extended release characteristics, and more specifically, to a sustained-release pharmaceutical composition containing acebrophylline and a hydrophobic sustained-release agent.
The present invention relates to a pharmaceutical composition containing acebrophylline thereby having both immediate and extended release characteristics, and more specifically, to a sustained-release pharmaceutical composition containing acebrophylline and a hydrophillic sustained-release agent having a viscosity of no more than 13,000 cps.
NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT
The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a method of preparing same and a pharmaceutical composition for preventing and treating metabolic disease including same as an effective ingredient. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has an excellent effect on activation of GPR40 protein and thus has excellent promoting effect of insulin secretion; is nontoxic when co-administrated with other drugs and is possibly co-administrated with other drugs; and has excellent effective effect of activating GPR40 protein in vivo. Therefore, a composition including the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof may be availably used in a pharmaceutical composition for preventing and treating metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin tolerance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, syndrome X, etc.
C07D 317/72 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
40.
COMPOSITION FOR EXTERNAL USE PREPARATION WITH IMPROVED TRANSDERMAL PERMEABILITY
The present invention relates to a composition for an external use skin preparation, wherein the composition comprises tranexamic acid or a salt thereof and a transdermal absorption promoter, and thus has remarkably enhanced transdermal permeability and is improved in the feeling use, skin irritation and storage stability.
The present invention provides a composition for preventing, ameliorating, or treating obesity containing extracts of Litchi chinensis and Artemisia iwayomogi as active ingredients. The composition of the present invention, which is a mixture of the extracts of Litchi chinensis and Artemisia iwayomogi, exhibits a stronger effect in losing body weight compared with individual extracts of Litchi chinensis and Artemisia iwayomogim, thereby ultimately exhibiting activity to prevent or treat obesity. The present invention provides foundational data as medicine and food of the extracts of Litchi chinensis and Artemisia iwayomogim which have efficacies in preventing and treating obesity.
NOVEL PIPERAZINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISORDERS
The present invention relates to a novel piperazine derivative, to a pharmaceutically acceptable salt or an optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition containing same as an active ingredient for preventing or treating metabolic disorders. The novel piperazine derivative and the pharmaceutically acceptable salt or the isomer thereof, according to the present invention, have excellent in vivo absorptivity and outstanding safety in the human body, since the present invention has a higher water solubility than those of compounds conventionally known as GPR119 activators and has low cytotoxicity. Moreover, since the present invention has the excellent effect of promoting cAMP by activating GPR119, thereby having the significantly outstanding effect of reducing blood glucose in a single dose, the present invention can be effectively used as a pharmaceutical composition for preventing or treating obesity, type I diabetes, type II diabetes, inadequate glucose tolerance, insulin tolerance, hyperglycemia, hyperlipemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, or X syndrome which are treatable by activating GPR119.
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
The present invention relates to a composition comprising natural extracts as active ingredients for improving the condition of the hair and scalp, to a method for preparing same, and to a method for improving the condition of the hair and scalp by applying natural extracts thereto. The composition for improving the condition of the hair and scalp according to the present invention comprises natural extracts as active ingredients, and therefore the composition of the present invention is free of side effects or toxicity, and can be applied in an economically advantageous and easy manner as the composition does not require a surgical procedure.
The present invention relates to an immediate-release and sustained-release pharmaceutical composition comprising acebrophylline, and to a method for preparing same. The composition of the present invention includes an immediate-release portion and a sustained-release portion that exhibit independent release characteristics, thus increasing both a rapid medicinal effect and convenience in taking medicine. Further, dissolution stability is improved in order to achieve improved treatment effects.
The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof and a pharmaceutical composition for treating metabolism-related disorder containing the same. Specifically, the present invention relates to a compound of the formula 1, which can activate GPR119 to treat metabolism-related disorders, including diabetes and related diseases, diabetes-related microvascular complications, diabetes-related macrovascular complications, cardiovascular abnormalities, metabolic syndrome and its constituent diseases, and obesity.
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 211/36 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same for inhibiting human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1). The disclosed compound and the pharmaceutical composition including the same for inhibiting human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1) are excellent in activity and solubility, and is more efficient in formulation and transfer.
C07C 311/05 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.
The present invention relates to an oral preparation containing zoledronic acid, which reduces enteric injuries and improves bioavailability. More particularly, the present invention relates to an oral preparation having an enteric coating, which comprises zoledronic acid and the pharmaceutically acceptable salts thereof, and which has a core, the pH level of which is 3.5 to 7.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
50.
SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION COMPRISING LEVETIRACETAM OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF HAVING IMPROVED DISSOLUTION STABILITY AND METHOD FOR MANUFACTURING THE SAME
The present invention relates to a sustained-release pharmaceutical composition comprising a levetiracetam or a pharmaceutically acceptable salt thereof, and to a method of preparing the same. More specifically, the present invention relates to a sustained-release pharmaceutical composition comprising a levetiracetam or a pharmaceutically acceptable salt thereof with an improved dissolution stability that is constant dissolution rate under various releasing conditions, and to a method of preparing the same in a simple and easy manner.
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and the compound-containing pharmaceutical composition for treating a metabolic disorder. Specifically, the disclosed compound is represented by [Formula 1]. The compound activates GPR119, and thus can be used for treating metabolic disorders, that is, diabetes mellitus, diabetes mellitus-related diseases, diabetes mellitus-related microvessel complications, diabetes mellitus-related large vessel complications, cardiovascular disorders, metabolic syndrome and its constituent diseases, obesity, and other diseases. In Formula 1, P1, P2, P3, P4, L1, R4, n4, X, Y, Z1 and Z2 are the same as defined above.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Disclosed is a sustained-release pharmaceutical composition containing pramipexole or a pharmaceutically acceptable salt thereof and, more particularly, a pharmaceutical composition that uses a stabilizer for inhibiting production of related substances caused by additives and greatly enhances stability. The pharmaceutical composition shows an effectively controlled dissolution profile, realizing its usefulness in the manufacture of pramipexole-containing sustained-release preparations in various dosage forms easy for drug release control; includes a stabilizer to minimize impurity production of the drug-containing products during drug storage, remarkably improving chemical stability; and thereby eliminates a need for separate studies on the physical chemical structure analysis and/or on the toxicological effects of the corresponding impurities.
Disclosed is a pharmaceutical composition containing crystalline nebivolol hydrochloride and a method for preparing the same that enhances the dissolution rate of the crystalline nebivolol hydrochloride and minimizes the variance of dissolution rate to greatly enhance a desired therapeutic effect. The pharmaceutical composition includes: an active ingredient including an effective amount of crystalline nebivolol hydrochloride; and a pharmaceutically acceptable additive including starch, the pharmaceutical composition containing the crystalline nebivolol hydrochloride and the starch at a weight ratio of 1:15 to 1:40.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/718 - Starch or degraded starch, e.g. amylose, amylopectin
A61K 9/22 - Sustained or differential release type
A61P 9/00 - Drugs for disorders of the cardiovascular system
54.
PHARMACEUTICAL COMPOSITION WITH CONTROLLED-RELEASE PROPERTIES COMPRISING MOSAPRIDE OR LEVODROPROPIZINE, AND PREPARING METHOD THEREOF
Disclosed is a sustained-release pharmaceutical composition comprising mosapride or levodropropizine as an active ingredient, a method of preparing the same, and a pharmaceutical composition with dual release property comprising a sustained-release part and an immediate release part respectively comprising the active ingredient. The sustained-release pharmaceutical composition may constantly release drugs despite change in internal organ movement state of a subject, and it may constantly release the active ingredient even if a long time passes after administration, and thus, it may sufficiently deliver drugs only with single dose or two doses per day. And, since the pharmaceutical composition with dual release property has an immediate part and a sustained-release part exhibiting independent release properties, it may simultaneously increase rapid pharmaceutical effect and convenience for internal use, and improved treatment effect may also be expected due to improved the dissolution stability.
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
The present invention relates to a pharmaceutical composition that enables easy control of a release pattern of galantamine or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition in the form of matrix comprises: granules including a therapeutically effective amount of galantamine or pharmaceutically acceptable salts thereof and aminoalkyl methacrylate copolymer; and ethylcellulose polymer particles having average particle diameter of 1 to 450 μm, wherein the amount of the galantamine is 8n mg and the average particle diameter of the ethylcellulose polymer particles is more than 15(n- 1)3 μm and not more than 15n3 μm.
A61K 9/26 - Discrete particles in supporting matrix
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vitamin tablets; vitamin preparations; pharmaceuticals for
the treatment of bone diseases; multivitamin preparations;
mixed vitamin preparations; mineral nutritional supplements;
mineral food-supplements; nutritional additives for medical
purposes; amino acids for medical purposes; haemoglobin.
57.
PHARMACEUTICAL COMPOSITION CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE
The present invention relates to a pharmaceutical composition containing telmisartan and hydrochlorothiazide, and particularly, the present invention relates to a pharmaceutical composition containing telmisartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a diuretic). The pharmaceutical composition of the present invention, having a compound containing polyvinylpyrrolidone (an inactive water soluble polymer) primarily coated on a telmisartan core, and a compound of hydrochlorothiazide (a diuretic) and polyvinylpyrrolidone secondarily coated thereon, can have a good diuretic dissolution rate, and is significantly smaller and lighter than commercial drugs of the prior art, so that administering dosages to patients can be easier, and the composition can be effectively used in the medical industry.
The invention relates to a pharmaceutical composition comprising telmisartan and cilnidipine. The pharmaceutical composition can manifest excellent blood pressure-lowering effect through synergism of telmisartan and cildinipine, and can be used for novel use of inhibiting vascular damage and hypertrophy.
The present invention relates to a pharmaceutical composition comprising telmisartan and lercanidipine. The pharmaceutical composition can manifest more excellent blood pressure-lowering effect through synergism of telmisartan and lercanidipine.
The present invention relates to a gel composition comprising minoxidil that can maintain stable gel phase while dissolving a high concentration of minoxidil. The gel composition comprises an effective amount of minoxidil, a thickener, and an aqueous solvent containing glycerin.
